Quarterly report · Q2
8129.TEDINET S100S94E
Period2023-04-01 → 2023-09-30
Filed2023-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 49
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥734.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Revenue | ¥1.39T | 2022-04-01 → 2023-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥681.5bn | 2022-04-01 → 2022-09-30 | Cons. | Net sales |
| Operating income | ¥6.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Operating income | ¥5.8bn | 2022-04-01 → 2022-09-30 | Cons. | Operating income |
| Ordinary income | ¥7.9bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥19.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥7.4bn | 2022-04-01 → 2022-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥13.0bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥6.0bn | 2022-04-01 → 2022-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥8.8bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Net income | ¥3.6bn | 2022-04-01 → 2022-09-30 | Cons. | Profit loss |
| Total assets | ¥801.4bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥715.3bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥740.6bn | at 2022-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥556.2bn | at 2023-09-30 | Cons. | Liabilities |
| Total liabilities | ¥472.4bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥245.1bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥242.9bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥245.6bn | at 2022-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥137.9bn | at 2023-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥86.2bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥133.5bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥81.8bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥97.9bn | at 2022-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.0bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥53.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥9m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥10.7bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | ¥3.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥4.3bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥407m | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥5.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥13.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.0bn | 2022-04-01 → 2022-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥134.19 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥112.26 | 2023-07-01 → 2023-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥196.7 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥51.01 | 2022-04-01 → 2022-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥21.79 | 2022-07-01 → 2022-09-30d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥121.19 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.67 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥46.88 | 2022-04-01 → 2022-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 30.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.9% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.1% | at 2022-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 46
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥29.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥29.3bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥1.8bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥46.6bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥46.6bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥7m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥895m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥5.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥4.0bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥436m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥709.4bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥684.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥24.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥6.8bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥3.0bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥2.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥678m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥139m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥764.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥734.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥29.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥8.3bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2022-09-30 | −¥28.3bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2022-09-30 | −¥850m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥45.1bn |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3m |
| jpcrp040300-q2r_E02608-000Dispensing Pharmacyreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥878m |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥4.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥1.1bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02608-000Medical Products Manufacturing And Salesreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥478m |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥656.6bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥632.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥23.8bn |
| jpcrp040300-q2r_E02608-000Medical Products Retailreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥5.1bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue | 2022-04-01 → 2022-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue external | 2022-04-01 → 2022-09-30 | ¥2.5bn |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥782m |
| jpcrp040300-q2r_E02608-000Other Related Businessreportable segment | segment profit | 2022-04-01 → 2022-09-30 | ¥246m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2022-09-30 | ¥709.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2022-09-30 | ¥681.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2022-09-30 | ¥28.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2022-09-30 | ¥6.7bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 581
| Item | Context | Value | Unit |
|---|---|---|---|
| Number of issued shares as of filing date issued shares total number of shares etc | FilingDateInstant | 78270142 | |
| Number of shares held | CurrentQuarterInstant_No1MajorShareholdersMember | 7529000 | |
| Shareholding ratio | CurrentQuarterInstant_No1MajorShareholdersMember | 0.1165 | |
| Number of shares held | CurrentQuarterInstant_No2MajorShareholdersMember | 3500000 | |
| Shareholding ratio | CurrentQuarterInstant_No2MajorShareholdersMember | 0.0542 | |
| Number of shares held | CurrentQuarterInstant_No3MajorShareholdersMember | 2585000 | |
| Shareholding ratio | CurrentQuarterInstant_No3MajorShareholdersMember | 0.0400 | |
| Number of shares held | CurrentQuarterInstant_No4MajorShareholdersMember | 2174000 | |
| Shareholding ratio | CurrentQuarterInstant_No4MajorShareholdersMember | 0.0336 | |
| Number of shares held | CurrentQuarterInstant_No5MajorShareholdersMember | 1637000 | |
| Shareholding ratio | CurrentQuarterInstant_No5MajorShareholdersMember | 0.0253 | |
| Number of shares held | CurrentQuarterInstant_No6MajorShareholdersMember | 1608000 | |
| Shareholding ratio | CurrentQuarterInstant_No6MajorShareholdersMember | 0.0249 | |
| Number of shares held | CurrentQuarterInstant_No7MajorShareholdersMember | 1556000 | |
| Shareholding ratio | CurrentQuarterInstant_No7MajorShareholdersMember | 0.0241 | |
| Number of shares held | CurrentQuarterInstant_No8MajorShareholdersMember | 1333000 | |
| Shareholding ratio | CurrentQuarterInstant_No8MajorShareholdersMember | 0.0206 | |
| Number of shares held | CurrentQuarterInstant_No9MajorShareholdersMember | 1181000 | |
| Shareholding ratio | CurrentQuarterInstant_No9MajorShareholdersMember | 0.0183 | |
| Number of shares held | CurrentQuarterInstant_No10MajorShareholdersMember | 1149000 | |
| Shareholding ratio | CurrentQuarterInstant_No10MajorShareholdersMember | 0.0178 | |
| Number of shares held | CurrentQuarterInstant | 24255000 | |
| Shareholding ratio | CurrentQuarterInstant | 0.3753 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithNoVotingRightsMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsTreasurySharesEtcMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_SharesWithRestrictedVotingRightsOtherMember | － | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesTreasurySharesSharesWithFullVotingRightsTreasurySharesEtcMember | 13638000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesReciprocalHoldingSharesWithFullVotingRightsTreasurySharesEtcMember | 34000 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 64540800 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesWithFullVotingRightsOtherMember | 645408 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant_OrdinarySharesSharesLessThanOneUnitMember | 57342 | |
| Number of shares issued shares voting rights | CurrentQuarterInstant | 78270142 | |
| Number of voting rights issued shares voting rights | CurrentQuarterInstant | 645408 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row1Member | 13638000 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row1Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row1Member | 13638000 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row1Member | 0.1742 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row2Member | 33000 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row2Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row2Member | 33000 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row2Member | 0.0004 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant_Row3Member | 1000 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant_Row3Member | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant_Row3Member | 1000 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant_Row3Member | 0.0000 | |
| Number of shares held in own name treasury shares etc | CurrentQuarterInstant | 13672000 | |
| Number of shares held in others names treasury shares etc | CurrentQuarterInstant | － | |
| Total number of shares held treasury shares etc | CurrentQuarterInstant | 13672000 | |
| Shareholding ratio treasury shares etc | CurrentQuarterInstant | 0.1746 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |